Published in N Engl J Med on August 14, 2003
Adipokines as Predictors of the Metabolic Syndrome in ALL Survivors | NCT00566566
Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med (2009) 7.95
Late mortality among 5-year survivors of childhood cancer: a summary from the Childhood Cancer Survivor Study. J Clin Oncol (2009) 3.30
Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood (2012) 2.82
Prospective medical assessment of adults surviving childhood cancer: study design, cohort characteristics, and feasibility of the St. Jude Lifetime Cohort study. Pediatr Blood Cancer (2010) 2.69
Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood (2006) 2.62
Solid cancers after allogeneic hematopoietic cell transplantation. Blood (2008) 2.56
Reduction in Late Mortality among 5-Year Survivors of Childhood Cancer. N Engl J Med (2016) 2.36
Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia (2009) 2.24
Twenty-five-year follow-up among survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. Blood (2008) 2.17
Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from Children's Oncology Group Study P9201. Blood (2007) 1.97
Neurocognitive outcomes decades after treatment for childhood acute lymphoblastic leukemia: a report from the St Jude lifetime cohort study. J Clin Oncol (2013) 1.76
High-risk populations identified in Childhood Cancer Survivor Study investigations: implications for risk-based surveillance. J Clin Oncol (2009) 1.68
Second malignant neoplasms and cardiovascular disease following radiotherapy. J Natl Cancer Inst (2012) 1.64
Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial. Clin Cancer Res (2010) 1.64
Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood (2007) 1.52
Safe lumbar puncture under analgo-sedation in children with acute lymphoblastic leukemia. Int J Clin Oncol (2013) 1.51
Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood (2005) 1.42
In vivo response to methotrexate forecasts outcome of acute lymphoblastic leukemia and has a distinct gene expression profile. PLoS Med (2008) 1.37
Insulin resistance and risk factors for cardiovascular disease in young adult survivors of childhood acute lymphoblastic leukemia. J Clin Oncol (2009) 1.36
Temporal trends in cause-specific late mortality among 5-year survivors of childhood cancer. J Clin Oncol (2010) 1.27
Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia. Blood (2011) 1.24
Central nervous system disease in hematologic malignancies: historical perspective and practical applications. Semin Oncol (2009) 1.21
Radiation-induced meningiomas: a shadow in the success story of childhood leukemia. Neuro Oncol (2009) 1.18
Childhood cancer in developing society: A roadmap of health care. Indian J Med Paediatr Oncol (2011) 1.13
Late effects of treatment in survivors of childhood cancer from a tertiary cancer center in South India. South Asian J Cancer (2014) 1.02
Predictors of marriage and divorce in adult survivors of childhood cancers: a report from the Childhood Cancer Survivor Study. Cancer Epidemiol Biomarkers Prev (2009) 1.01
Sexual functioning in young adult survivors of childhood cancer. Psychooncology (2010) 0.96
Incidence rates in dynamic populations. Int J Epidemiol (2012) 0.95
Childhood central nervous system leukemia: historical perspectives, current therapy, and acute neurological sequelae. Neuroradiology (2007) 0.95
A revised definition for cure of childhood acute lymphoblastic leukemia. Leukemia (2014) 0.95
Radiation associated tumors following therapeutic cranial radiation. Surg Neurol Int (2012) 0.92
Persistent psychological distress in long-term survivors of pediatric sarcoma: the experience at a single institution. Psychooncology (2006) 0.92
Mammalian target of rapamycin (mTOR) activity dependent phospho-protein expression in childhood acute lymphoblastic leukemia (ALL). PLoS One (2013) 0.91
Is an internal comparison better than using national data when estimating mortality in longitudinal studies? J Epidemiol Community Health (2006) 0.90
Cohort Profile: the French childhood cancer survivor study for leukaemia (LEA Cohort). Int J Epidemiol (2014) 0.89
Molecular diagnosis and risk-adjusted therapy in pediatric hematologic malignancies: a primer for pediatricians. Eur J Pediatr (2011) 0.89
Thyroid cancer: current molecular perspectives. J Oncol (2010) 0.87
Deficient innate immunity, thymopoiesis, and gene expression response to radiation in survivors of childhood acute lymphoblastic leukemia. Cancer Epidemiol (2010) 0.87
Novel targeted drug therapies for the treatment of childhood acute leukemia. Expert Rev Hematol (2009) 0.85
Age-dependent changes in health status in the Childhood Cancer Survivor cohort. J Clin Oncol (2014) 0.83
Influence of Cranial Radiotherapy on Outcome in Children With Acute Lymphoblastic Leukemia Treated With Contemporary Therapy. J Clin Oncol (2016) 0.82
Childhood leukaemia: long-term excess mortality and the proportion 'cured'. Br J Cancer (2008) 0.82
Diffuse high-grade gliomas as second malignant neoplasms after radio-chemotherapy for pediatric malignancies. Childs Nerv Syst (2006) 0.81
Nicotinamide inhibits alkylating agent-induced apoptotic neurodegeneration in the developing rat brain. PLoS One (2011) 0.81
Milestones in the curability of pediatric cancers. J Clin Oncol (2014) 0.81
Excess congenital non-synonymous variation in leukemia-associated genes in MLL- infant leukemia: a Children's Oncology Group report. Leukemia (2013) 0.80
Novel therapies for relapsed acute lymphoblastic leukemia. Curr Hematol Malig Rep (2009) 0.80
Health-related quality of life in long-term survivors of relapsed childhood acute lymphoblastic leukemia. PLoS One (2012) 0.79
Incidental detection of late subsequent intracranial neoplasms with magnetic resonance imaging among adult survivors of childhood cancer. J Cancer Surviv (2014) 0.78
Valproic acid enhances the efficacy of radiation therapy by protecting normal hippocampal neurons and sensitizing malignant glioblastoma cells. Oncotarget (2015) 0.78
Childhood leukemia--successes and challenges for survivors. N Engl J Med (2003) 0.78
Femoral resurfacing in young patients with hematologic cancer and osteonecrosis. Clin Orthop Relat Res (2008) 0.78
Long-term survivors of acute lymphoblastic leukemia. N Engl J Med (2003) 0.77
DNA repair polymorphisms influence the risk of second neoplasm after treatment of childhood acute lymphoblastic leukemia. J Cancer Res Clin Oncol (2012) 0.77
Potential toxicities of prophylactic cranial irradiation. Transl Lung Cancer Res (2012) 0.77
Post-traumatic Stress Symptoms and Post-traumatic Growth in 223 Childhood Cancer Survivors: Predictive Risk Factors. Front Psychol (2016) 0.76
Health-related quality of life and cognitive outcomes among child and adolescent survivors of leukemia. Support Care Cancer (2009) 0.76
Improving access to novel agents for childhood leukemia. Cancer (2015) 0.76
Role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Ther Clin Risk Manag (2007) 0.76
Minimal Residual Disease Evaluation in Childhood Acute Lymphoblastic Leukemia: An Economic Analysis. Ont Health Technol Assess Ser (2016) 0.75
Definition of cure in childhood acute myeloid leukemia. Cancer (2014) 0.75
Body composition and bone health in long-term survivors of acute lymphoblastic leukaemia in childhood and adolescence: the protocol for a cross-sectional cohort study. BMJ Open (2015) 0.75
CCND1 G870A polymorphism is associated with toxicity of methotrexate in childhood acute lymphoblastic leukemia. Int J Clin Exp Pathol (2015) 0.75
Topics in pediatric leukemia--acute lymphoblastic leukemia and late effects in long-term survivors. MedGenMed (2005) 0.75
Primary anaplastic astrocytoma of the brain after prophylactic cranial irradiation in a case of acute lymphoblastic leukemia: Case report and review of the literature. Indian J Med Paediatr Oncol (2014) 0.75
Continue to study childhood ALL. Blood (2008) 0.75
ABCB1 genetic variants in leukemias: current insights into treatment outcomes. Pharmgenomics Pers Med (2017) 0.75
The Role of the Central Nervous System Microenvironment in Pediatric Acute Lymphoblastic Leukemia. Front Pediatr (2017) 0.75
Chronic health conditions in adult survivors of childhood cancer. N Engl J Med (2006) 19.97
Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature (2007) 17.68
Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell (2002) 11.83
Treatment of acute lymphoblastic leukemia. N Engl J Med (2006) 11.30
Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med (2009) 10.54
BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature (2008) 10.12
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature (2012) 9.89
Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med (2009) 7.95
Acute lymphoblastic leukemia. N Engl J Med (2004) 7.83
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med (2014) 5.37
A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol (2009) 5.22
Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. Nat Genet (2011) 4.93
Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol (2009) 4.89
Implementing genomic medicine in the clinic: the future is here. Genet Med (2013) 4.89
Development of risk-based guidelines for pediatric cancer survivors: the Children's Oncology Group Long-Term Follow-Up Guidelines from the Children's Oncology Group Late Effects Committee and Nursing Discipline. J Clin Oncol (2004) 4.63
Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell (2012) 4.41
Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood (2004) 4.21
Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med (2004) 4.16
Gene expression profiling of pediatric acute myelogenous leukemia. Blood (2004) 3.77
Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol (2010) 3.76
Germline genomic variants associated with childhood acute lymphoblastic leukemia. Nat Genet (2009) 3.71
Late neurocognitive sequelae in survivors of brain tumours in childhood. Lancet Oncol (2004) 3.56
Long-term outcomes among adult survivors of childhood central nervous system malignancies in the Childhood Cancer Survivor Study. J Natl Cancer Inst (2009) 3.52
The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet (2013) 3.43
Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood (2011) 3.40
Medical care in long-term survivors of childhood cancer: a report from the childhood cancer survivor study. J Clin Oncol (2008) 3.27
Histopathologic grading of medulloblastomas: a Pediatric Oncology Group study. Cancer (2002) 3.23
Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group. J Clin Oncol (2011) 3.05
Moving towards individualized medicine with pharmacogenomics. Nature (2004) 2.99
Pharmacogenomics and individualized drug therapy. Annu Rev Med (2006) 2.95
Direct ubiquitination of pattern recognition receptor FLS2 attenuates plant innate immunity. Science (2011) 2.93
Conformal radiotherapy after surgery for paediatric ependymoma: a prospective study. Lancet Oncol (2009) 2.88
Robust estimation of the false discovery rate. Bioinformatics (2006) 2.87
NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol (2010) 2.85
Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood (2012) 2.82
Results of therapy for acute lymphoblastic leukemia in black and white children. JAMA (2003) 2.77
Improving false discovery rate estimation. Bioinformatics (2004) 2.77
Stroke as a late treatment effect of Hodgkin's Disease: a report from the Childhood Cancer Survivor Study. J Clin Oncol (2005) 2.76
Health care of young adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. Ann Fam Med (2004) 2.73
Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. JAMA (2009) 2.72
Acute mixed lineage leukemia in children: the experience of St Jude Children's Research Hospital. Blood (2009) 2.70
Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. Blood (2010) 2.58
Clinical implementation of pharmacogenomics: overcoming genetic exceptionalism. Lancet Oncol (2010) 2.52
Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition. Genome Res (2011) 2.52
Gene expression signatures predictive of early response and outcome in high-risk childhood acute lymphoblastic leukemia: A Children's Oncology Group Study [corrected]. J Clin Oncol (2008) 2.51
The Pediatric Cancer Genome Project. Nat Genet (2012) 2.49
Aging and risk of severe, disabling, life-threatening, and fatal events in the childhood cancer survivor study. J Clin Oncol (2014) 2.45
Breast cancer surveillance practices among women previously treated with chest radiation for a childhood cancer. JAMA (2009) 2.42
The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation. Clin Pharmacol Ther (2013) 2.39
Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia. Nat Genet (2013) 2.38
Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia. JAMA (2007) 2.38